

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Biology

LLUCC-BIOSPECIMEN
LABORATORY - SPECIMEN
COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection
Protocol

[Mark E. Reeves, MD, PhD](#)

Brain

SWOG-NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

<https://clinicaltrials.gov/ct2/show/NCT02179086>

[Joseph Kang, MD](#)

Breast

NSABP-B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

<https://clinicaltrials.gov/ct2/show/NCT01872975>

[Sharon Lum, MD](#)

SWOG-A011106

ALTErnate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

<https://clinicaltrials.gov/ct2/show/NCT01953588>

[Gayathri Nagaraj, MD](#)

SWOG-A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

<https://clinicaltrials.gov/ct2/show/NCT01901094>

[Sharon Lum, MD](#)

SWOG-S1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

<http://www.clinicaltrials.gov/ct2/show/NCT01674140>

[Gayathri Nagaraj, MD](#)

YALE University-SHAVE2

A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients

<https://clinicaltrials.gov/ct2/show/NCT02772731>

[Sharon Lum, MD](#)

Merck-MK3475-355

A Randomized, Double-Blind, Phase III Study of pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer-(KEYNOTE-355)

<https://clinicaltrials.gov/ct2/show/NCT02819518>

[Gayathri Nagaraj, MD](#)

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies**

GI

Colon

SWOG-S0820	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) http://www.clinicaltrials.gov/ct2/show/NCT01349881	Chung-Tsen Hsueh, MD, PhD
------------	--	---

Esophagus

Radiation Medicine	A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer https://clinicaltrials.gov/ct2/show/NCT01684904	Gary Yang, MD
--------------------	---	-------------------------------

Gastric

Investigator Initiated HIPEC	Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer https://clinicaltrials.gov/ct2/show/NCT02672865	Maheswari Senthil, MD
------------------------------	---	---------------------------------------

Liver

Radiation Medicine	Randomized controlled trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma https://clinicaltrials.gov/ct2/show/NCT00857805	David Bush, MD & Michael De Vera, MD
--------------------	---	---

Radiation Medicine	Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases https://clinicaltrials.gov/ct2/show/NCT01697371	Gary Yang, MD
--------------------	---	-------------------------------

Pancreas

Radiation Medicine	A phase II trial of gemcitabine and erlotinib (GB) plus proton-chemotherapy (PCT) and capox for locally advanced pancreatic cancer (LAPC) https://clinicaltrials.gov/ct2/show/NCT01683422	Gary Yang, MD
--------------------	--	-------------------------------

GU

Bladder

SWOG-S1314	A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer https://clinicaltrials.gov/ct2/show/NCT02177695	John Wong, MD
------------	---	-------------------------------

Merck-MK3475-361	A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma https://clinicaltrials.gov/ct2/show/NCT02853305	John Wong, MD
------------------	--	-------------------------------

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

GU

Prostate

Radiation Medicine	Phase I-II trial of hypofractionated conformal proton beam radiation therapy for favorable-risk prostate Cancer https://clinicaltrials.gov/ct2/show/NCT00831623	Jerry Slater, MD
Radiation Medicine	Cytogenetic damage as a biomarker of radiation sensitivity in prostate cancer	Marcelo Vazquez , MD, PhD

Testicular

Investigator Initiated-4T-14-1	Phase II Trials of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-2cm) https://clinicaltrials.gov/ct2/show/NCT02537548	Brian Hu, MD
--------------------------------	---	------------------------------

GYN

Ovarian

Investigator Initiated HIPEC	Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer https://clinicaltrials.gov/ct2/show/NCT02672098	Mazdak Momeni, MD
------------------------------	---	-----------------------------------

Uterus

GOG-0263	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy https://clinicaltrials.gov/ct2/show/NCT01101451	Yevgeniya Ioffe, MD
----------	---	-------------------------------------

Leukemia

SWOG-S1318	A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF) https://clinicaltrials.gov/ct2/show/NCT02143414	Muhammad Kamal, MD
------------	--	------------------------------------

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Lung

Novartis-CLDK378A2112	A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02299505	Hamid Mirshahidi, MD
SWOG-A151216	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-A081105	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-EA5142	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers https://clinicaltrials.gov/ct2/show/NCT02595944	Hamid Mirshahidi, MD
SWOG-E4512	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein https://clinicaltrials.gov/ct2/show/NCT02201992	Hamid Mirshahidi, MD
SWOG-S1400	Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer http://clinicaltrials.gov/ct2/show/NCT02154490	Hamid Mirshahidi, MD
Mirati – 265-109	Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor https://clinicaltrials.gov/ct2/show/NCT02544633	Hamid Mirshahidi, MD
Xcovery-X396-CLI-101	Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT01625234	Hamid Mirshahidi, MD
SWOG-S1507	A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies https://clinicaltrials.gov/ct2/show/NCT02642042	Hamid Mirshahidi, MD
Genentech-ML39237	A Phase II Single-arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-small Cell Lung Cancer: Clinical Evaluation of Novel Blood-based Diagnostics https://clinicaltrials.gov/ct2/show/NCT02848651	Hamid Mirshahidi, MD

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies**

Melanoma

SWOG-S1320	A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma http://clinicaltrials.gov/ct2/show/NCT02196181	Frank Howard, IV, MD, PhD
------------	---	---

Multiple

SWOG-EAY131-MATCH	Molecular Analysis for Therapy Choice (MATCH) https://clinicaltrials.gov/ct2/show/NCT02465060	Gayathri Nagaraj, MD
-------------------	--	--------------------------------------

SWOG-S1609	DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02834013	John Wong, MD
------------	---	-------------------------------

Soft Tissue Sarcoma

Radiation Medicine	A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall https://clinicaltrials.gov/ct2/show/NCT01819831	Gary Yang, MD
--------------------	---	-------------------------------

Registry

Radiation Medicine	Radiation Medicine Patient Registry https://clinicaltrials.gov/ct2/show/NCT02436941	Jerry Slater, MD
--------------------	--	----------------------------------